{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:13:50Z","timestamp":1789445630968,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Current prognostic models for metastatic renal cell carcinoma (mRCC) are likely inaccurate due to recent treatment advances and improved survival outcomes. The JEWEL study used a data set from patients who received tyrosine kinase inhibitors (TKIs) to explore the prognostic impact of the tumor immune environment in the absence of immune checkpoint inhibitor intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The primary analysis population comprised 569 of the 770 Japanese patients enrolled in the ARCHERY study who received first\u2010line TKIs. Multivariable Cox proportional hazard models were used to identify factors associated with the primary (overall survival [OS]) and secondary outcomes (treatment duration) using 34 candidate explanatory variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median OS was 34.1\u2009months (95% CI, 30.4\u201337.6) in the primary analysis population. A considerable negative prognostic impact (descriptive <jats:italic>p<\/jats:italic>\u2009\u2264\u20090.0005) on OS was seen with lactate dehydrogenase (LDH) &gt;1.5\u2009\u00d7\u2009upper limit of normal (adjusted HR [aHR], 3.30; 95% CI, 2.19\u20134.98), Eastern Cooperative Oncology Group performance status (ECOG PS) \u22652 (aHR, 2.14; 95% CI, 1.56\u20132.94), World Health Organization (WHO)\/International Society of Urological Pathology (ISUP) Grade 4 (aHR, 1.89; 95% CI, 1.43\u20132.51), C\u2010reactive protein (CRP) level\u2009\u22650.3 (aHR, 1.78; 95% CI, 1.40\u20132.26), and age\u2009\u226575\u2009years (aHR, 1.65; 95% CI, 1.24\u20132.18) in the multivariable analysis. PD\u2010L1 and immunophenotype affected OS in univariable analyses but were not selected in the multivariable model as explanatory variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>JEWEL identified sex, age, ECOG PS, liver and bone metastases, CRP levels, WHO\/ISUP grade, LDH, and albumin levels as key prognostic factors for OS after first\u2010line TKI therapy for mRCC.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.15244","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T05:40:59Z","timestamp":1689140459000},"page":"977-984","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive investigation of clinicopathological and immunological features to determine prognostic impact in metastatic renal cell carcinoma: The <scp>JEWEL<\/scp> study"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2841-1998","authenticated-orcid":false,"given":"Kojiro","family":"Ohba","sequence":"first","affiliation":[{"name":"Department of Urology and Renal Transplantation Nagasaki University Hospital  Nagasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Monji","sequence":"additional","affiliation":[{"name":"Department of Urology Kyushu University Graduate School of Medical Sciences  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-7958","authenticated-orcid":false,"given":"Takahiro","family":"Osawa","sequence":"additional","affiliation":[{"name":"Department of Urology Hokkaido University Graduate School of Medicine  Sapporo\u2010shi Hokkaido Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Yamana","sequence":"additional","affiliation":[{"name":"Departments of Urology and Molecular Urology Niigata University Graduate School of Medical and Dental Sciences  Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5427-1680","authenticated-orcid":false,"given":"Yosuke","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Urology Tokyo Medical and Dental University Graduate School  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3632-2901","authenticated-orcid":false,"given":"Hajime","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Urology Tokyo Medical and Dental University Graduate School  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4103-2423","authenticated-orcid":false,"given":"Yuki","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Clinical Development Division Chugai Pharmaceutical Co, Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Fukuyama","sequence":"additional","affiliation":[{"name":"Medical Affairs Division Chugai Pharmaceutical Co, Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9203-4245","authenticated-orcid":false,"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Medical Urology National Cancer Center Hospital East  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3665-9523","authenticated-orcid":false,"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Urology Kindai University Faculty of Medicine  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Urology and Renal Transplantation Nagasaki University Hospital  Nagasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[{"name":"Department of Urology Kyushu University Graduate School of Medical Sciences  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.4809"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.289"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00419"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982"},{"key":"e_1_2_15_10_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Review Report (Opdivo and Yervoy) [Internet].2018Apr [cited 2022 Mar 15]. Available from:https:\/\/www.pmda.go.jp\/files\/000232985.pdf"},{"key":"e_1_2_15_11_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Review Report (Cabometyx and Nivolumab) [Internet].2021[cited 2022 May 5]. Available from:https:\/\/www.pmda.go.jp\/drugs\/2021\/P20210818001\/400256000_30200AMX00433_A100_1.pdf"},{"key":"e_1_2_15_12_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Review Report (Keytruda and Axitinib) [Internet].2019[cited 2022 May 5]. Available from:https:\/\/www.pmda.go.jp\/drugs\/2020\/P20200109002\/170050000_22800AMX00696000_A100_1.pdf"},{"key":"e_1_2_15_13_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Review Report (Lenvatinib and Pembrolizumab) [Internet].2022[cited 2022 May 5]. Available from:https:\/\/www.pmda.go.jp\/drugs\/2022\/P20220216001\/170050000_22800AMX00696000_A100_1.pdf"},{"key":"e_1_2_15_14_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Review Report (Bavencio and Axitinib).2019[cited 2022 May 5]. Available from:https:\/\/www.pmda.go.jp\/drugs\/2019\/P20191217003\/380079000_22900AMX00990_A100_1.pdf"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00446"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001079"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30413-9"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0241-z"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041537"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-01993-x"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13830"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2015.487"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2309-4"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2011.145"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02351.x"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0430-0"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318299f0fb"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2063"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100101"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2015.11.001"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.15244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T16:26:33Z","timestamp":1698855993000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.15244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/iju.15244"],"URL":"https:\/\/doi.org\/10.1111\/iju.15244","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"2023-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}